Scheduled Earnings Releases, Survey and Study Results, and Enrollment into Clinical Trial - Research Report on Biogen Idec,

  Scheduled Earnings Releases, Survey and Study Results, and Enrollment into
Clinical Trial - Research Report on Biogen Idec, Questcor, Medivation, Agenus,
                            and Arrowhead Research

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 11, 2013

NEW YORK, October 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR),
Medivation, Inc. (NASDAQ: MDVN), Agenus Inc. (NASDAQ: AGEN), and Arrowhead
Research Corp. (NASDAQ: ARWR). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Biogen Idec Inc. Research Report 

On October 7, 2013, Biogen Idec Inc. (Biogen Idec) announced that it will
release its Q3 2013 financial results on Monday, October 28, 2013, before the
market opens. Biogen Idec reported that it will also host a live webcast,
wherein the Company's management will discuss the financial results on the
same day at 9:00 a.m. ET. The Company further notified that interested parties
can access the live webcast of the call through its Investor Relations
website, wherein Biogen Idec will also make an archived version of the call
available for 30 days. The Full Research Report on Biogen Idec Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/b95b_BIIB]

--

Questcor Pharmaceuticals, Inc. Research Report

On October 8, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that
it will release its Q3 2013 financial results after the market closes on
Tuesday, October 29, 2013. Questcor informed that it will also host a
conference call and slide presentation via webcast on the same day at 4:30
p.m. ET (1:30 p.m. PT), to discuss the results and highlights of the quarter,
as well as its current corporate developments. The Company stated that the
webcast will be available through its Investor Relations website, while an
audio replay of the call will be accessible for seven business days by dialing
the numbers available at the Company's website. The Full Research Report on
Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/a415_QCOR]

--

Medivation, Inc. Research Report

On September 26, 2013, Medivation, Inc. (Medivation) and Astellas Pharma US,
Inc. announced results of a national survey of men with advanced prostate
cancer and their caregivers. According to Medivation, though the patients who
participated in the survey are generally optimistic, a good number among them
may feel isolated in coping with their disease. The companies reported that
45% of the participants said that they keep silent about their prostate cancer
and treatments, and 59% have shown concern about becoming a burden to family
and friends, while 43% of patient respondents have the same level of concern
about dying. Thomas A. Farrington, Founder and President of Prostate Health
Education Network (PHEN), commented, "This survey provides much-needed
information that will help us better support them, particularly as there is
evidence that men are now living longer with advanced disease." The Full
Research Report on Medivation, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/4277_MDVN]

--

Agenus Inc. Research Report

On October 7, 2013, Agenus Inc. (Agenus) announced that new Phase 3 data for
GlaxoSmithKline's (GSK's) RTS,S malaria vaccine candidate, which contains
Agenus' QS-21 Stimulon1 adjuvant, were presented at a Multilateral Initiative
on Malaria Pan African Conference in Durban, South Africa. Agenus informed
that RTS,S helps to protect young children and infants from clinical malaria
up to 18 months post vaccination. Garo H. Armen, Ph.D., Chairman and CEO of
Agenus, commented, "These findings indicate that RTS,S has the potential to
help prevent millions of malaria cases. We are very pleased that our QS-21
Stimulon adjuvant is a key component of AS01, a proprietary adjuvant system
used in RTS,S." Armen continued, "These results provide further support that
QS-21 Stimulon can help advance challenging development programs targeting
difficult diseases. Currently there are 21 development programs underway
involving vaccines that include QS-21 Stimulon for many different types of
cancer, infectious diseases and degenerative disorders." The Full Research
Report on Agenus Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/c668_AGEN]

--

Arrowhead Research Corp. Research Report

On October 8, 2013, Arrowhead Research Corp. (Arrowhead) announced that it has
successfully completed enrollment of 36 subjects in a Phase 1 clinical trial
of ARC-520, its RNAi-based candidate against chronic hepatitis B virus
infection. According to Arrowhead, initial data indicate that ARC-520 is
generally safe and well tolerated at all six dose levels studied, enabling the
Company to proceed with plans to initiate a Phase 2a pilot efficacy study in
chronic HBV patients. Christopher Anzalone, Ph.D., President and CEO of
Arrowhead, said, "We are very pleased with these results and the pace at which
we were able to complete the Phase 1 study. This positive readout on safety
and tolerability of ARC-520 and the Dynamic Polyconjugate (DPC) delivery
platform has broad implications for Arrowhead. It gives us additional
confidence as we move into an upcoming Phase 2a study and we believe it
represents a key de-risking event for expanding our pipeline of RNAi
therapeutics based on the DPC platform." The Full Research Report on Arrowhead
Research Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/0c95_ARWR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.